Manages acute pain severe enough to require an opioid analgesic. ANDA 219119, held by Novitium Pharma. Tapentadol Hydrochloride.
As of Nov 16, 2026, ANDA 219119 (Tapentadol Hydrochloride), held by Novitium Pharma, was first approved by FDA on Jan 26, 2026, with 1 approved supplement and 0 published complete response letters.
Tapentadol hydrochloride oral solution is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. Limitations of Use Because of the risks of addiction, abuse, misuse, overdose, and death, which can occur at any dosage or duration and persist over the course of therapy,, reserve opioid analgesics, including tapentadol hydrochloride oral solution for use in patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Pediatric use information is approved for Collegium Pharmaceutical, Inc.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 26, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tapentadol HydrochlorideEQ 20MG BASE/ML · solution;oral | Tapentadol Hydrochloride | Rx |
| Jun 18, 2026 | Supplement 1REMS | Approved | None posted |
| Jan 26, 2026 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters